Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) and Metagenomi (NASDAQ:MGX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Risk and Volatility
Cumberland Pharmaceuticals has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Cumberland Pharmaceuticals and Metagenomi, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cumberland Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Metagenomi | 1 | 0 | 3 | 1 | 2.80 |
Insider and Institutional Ownership
15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Cumberland Pharmaceuticals and Metagenomi”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cumberland Pharmaceuticals | $44.52 million | 2.04 | -$2.84 million | ($0.49) | -12.35 |
| Metagenomi | $25.21 million | 1.79 | -$87.87 million | ($2.30) | -0.52 |
Cumberland Pharmaceuticals has higher revenue and earnings than Metagenomi. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cumberland Pharmaceuticals and Metagenomi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cumberland Pharmaceuticals | -17.60% | -12.01% | -4.24% |
| Metagenomi | -384.61% | -51.23% | -36.62% |
Summary
Cumberland Pharmaceuticals beats Metagenomi on 9 of the 15 factors compared between the two stocks.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
